Peter Marks, the former director of the FDA’s Center for Biologics Evaluation and Research (CBER), will join Eli Lilly as senior vice president of molecule discovery and head of infectious disease. Marks resigned from the FDA earlier this year amid a dispute with HHS Secretary Robert F. Kennedy Jr. and arrives at Lilly with deep regulatory and vaccine-development experience, including leadership roles during the COVID‑19 vaccine effort. Lilly said Marks’ appointment strengthens its capabilities across existing portfolios and emerging areas. Analysts noted the hire brings regulatory insight and experience in advanced biologics and gene therapies to Lilly’s R&D operations. Marks’ move also highlights the ongoing revolving door between regulators and industry and the potential for accelerated translational programs when industry taps former agency leaders.